PharmaTher Holdings Ltd. has launched Personaliz3D Peptides™, a new division focused on personalized peptide therapies using 3D printing and artificial intelligence. This initiative aims to overcome limitations in traditional peptide compounding by offering customized doses, combination formulations, and alternative delivery methods such as gummies and patches. The division plans to integrate telemedicine, physician oversight, and qualified pharmacies into a seamless ecosystem to improve patient access and treatment precision. This launch follows positive FDA advisory committee recommendations that could pave the way for regulated compounded peptides in the U.S., signaling potential growth and innovation in personalized medicine.
Devia, an AI platform spun out from Visium, has launched to help biopharma companies, CDMOs, and CROs manage GxP quality deviations more efficiently. It automates the entire deviation lifecycle from reporting to root cause analysis and CAPA, reducing...
The Hong Kong Tourism Board is hosting its biggest-ever "Hong Kong WinterFest" from November 18, 2026, to January 5, 2027, featuring three themed winter towns in Central, Tsim Sha Tsui, and Causeway Bay. The event includes immersive light shows, a 22...
The Hong Kong Tourism Board is hosting its biggest-ever Hong Kong WinterFest from November 18, 2026, to January 5, 2027, expanding its Winter Wonderland to three key areas: Central, Tsim Sha Tsui, and Causeway Bay. Each location features unique theme...
ABN AMRO posted a net profit of €940 million in Q3 2026, a 52% increase year-on-year, driven by strong lending, deposits growth, and the acquisition of NIBC. The bank raised its full-year net interest income guidance to over €6.9 billion, supported b...
Artesian Resources Corporation reported Q3 2026 earnings of $0.65 per share, missing the $0.67 estimate and down from $0.68 a year earlier. Revenue rose 4.8% year-over-year to $31.9 million but fell short of the $32.2 million forecast. Net income dec...
